{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:09:31Z","timestamp":1791050971176,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1124\/mol.110.065540","type":"journal-article","created":{"date-parts":[[2010,7,31]],"date-time":"2010-07-31T02:11:08Z","timestamp":1280542268000},"page":"886-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Regulation of CYP2C19 Expression by Estrogen Receptor \u03b1: Implications for Estrogen-Dependent Inhibition of Drug Metabolism"],"prefix":"10.1016","volume":"78","author":[{"given":"Jessica","family":"Mwinyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Cavaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Steen","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souren","family":"Mkrtchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.110.065540_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.0306-5251.2001.01521.x","article-title":"The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity","volume":"53","author":"Belle","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clpt.2006.01.008","article-title":"Female sex and oral contraceptive use accelerate nicotine metabolism","volume":"79","author":"Benowitz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/mol.110.065540_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1098-2744(199708)19:4<236::AID-MC4>3.0.CO;2-A","article-title":"Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol","volume":"19","author":"Couse","year":"1997","journal-title":"Mol Carcinog"},{"key":"10.1124\/mol.110.065540_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/mol.110.065540_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","article-title":"Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei","volume":"11","author":"Dignam","year":"1983","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/mol.110.065540_bib6","doi-asserted-by":"crossref","first-page":"29321","DOI":"10.1074\/jbc.273.45.29321","article-title":"Sequence requirements for estrogen receptor binding to estrogen response elements","volume":"273","author":"Driscoll","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.110.065540_bib7","doi-asserted-by":"crossref","first-page":"35444","DOI":"10.1074\/jbc.M105418200","article-title":"Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens","volume":"276","author":"Fournier","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.110.065540_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","article-title":"Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers","volume":"51","author":"H\u00e4gg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1124\/dmd.107.016568","article-title":"Human CYP2A6 is induced by estrogen via estrogen receptor","volume":"35","author":"Higashi","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/mol.110.065540_bib10","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.89.10.4658","article-title":"Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor","volume":"89","author":"Ignar-Trowbridge","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.110.065540_bib11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1210\/endo.137.5.8612509","article-title":"Peptide growth factor cross-talk with the estrogen receptor requires the A\/B domain and occurs independently of protein kinase C or estradiol","volume":"137","author":"Ignar-Trowbridge","year":"1996","journal-title":"Endocrinology"},{"key":"10.1124\/mol.110.065540_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMe0708842","article-title":"Pharmacogenomic biomarkers for prediction of severe adverse drug reactions","volume":"358","author":"Ingelman-Sundberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.110.065540_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1124\/mol.110.065540_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-008-0076-4","article-title":"CYP2C19*17 is associated with decreased breast cancer risk","volume":"115","author":"Justenhoven","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/mol.110.065540_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1124\/mol.110.065540_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N","article-title":"Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs","volume":"13","author":"Klose","year":"1999","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/mol.110.065540_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-008-0571-x","article-title":"Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)","volume":"65","author":"Klotz","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1067\/mcp.2000.108949","article-title":"No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects","volume":"68","author":"Laine","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/mol.110.065540_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/mol.110.065540_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00008571-200309000-00005","article-title":"Differential expression and function of CYP2C isoforms in human intestine and liver","volume":"13","author":"L\u00e4pple","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/mol.110.065540_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mce.2008.04.003","article-title":"New insights into the classical and non-classical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice","volume":"290","author":"McDevitt","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/mol.110.065540_bib22","first-page":"5885","article-title":"A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma","volume":"11","author":"Nakabayashi","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1124\/mol.110.065540_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-2125.2003.01868.x","article-title":"The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects","volume":"56","author":"Palovaara","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0103","article-title":"Non-classical genomic estrogen receptor (ER)\/specificity protein and ER\/activating protein-1 signaling pathways","volume":"41","author":"Safe","year":"2008","journal-title":"J Mol Endocrinol"},{"key":"10.1124\/mol.110.065540_bib25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.32.5.484","article-title":"The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype","volume":"32","author":"Sandberg","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/mol.110.065540_bib26","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/mol.110.065540_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/0091270005280851","article-title":"Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail","volume":"45","author":"Shelepova","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/mol.110.065540_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002280050615","article-title":"CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences","volume":"55","author":"Tamminga","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/mol.110.065540_bib30","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1210\/me.2003-0446","article-title":"Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ERalpha and ERbeta","volume":"18","author":"van de Stolpe","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1124\/mol.110.065540_bib31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.1840380424","article-title":"Sex is a major determinant of CYP3A4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"Hepatology"},{"key":"10.1124\/mol.110.065540_bib32","first-page":"BR174","article-title":"Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients","volume":"12","author":"Wu","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1124\/mol.110.065540_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin Pharmacokinet"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24028177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24028177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.110.065540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:48:28Z","timestamp":1739958508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24028177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0026895X24028177"],"URL":"https:\/\/doi.org\/10.1124\/mol.110.065540","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulation of CYP2C19 Expression by Estrogen Receptor \u03b1: Implications for Estrogen-Dependent Inhibition of Drug Metabolism","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.110.065540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}